heparan sulfate Archives – The Bio Connection

Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in Sanfillippo Syndrome

February 8, 2018February 9, 2018 TheBioConnection Comment(0)

Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced updated clinical data from the ongoing Phase 1/2 trial for ABO-102 (AAV-SGSH), the company’s investigational gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA), a rare autosomal-recessive lysosomal storage disease. […]

New dual-action cancer-killing virus November 19, 2018
Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system. It is the first time that cancer-associated fibroblasts within solid tumors -- healthy cells that are tricked into protecting the cancer from the […]
A molecule for fighting muscular paralysis November 19, 2018
Myotubular myopathy is a severe genetic disease that leads to muscle paralysis. Although no treatment currently exists, researchers have identified a molecule that not only greatly reduces the progression of the disease but also boosts life expectancy in animal models by a factor of seven. Since the molecule -- known as tamoxifen -- is already […]
Dodging antibiotic resistance by curbing bacterial evolution November 16, 2018
Lowering mutation rates in harmful bacteria might be an as yet untried way to hinder the emergence of antimicrobial pathogens. One target for drug development might be a protein factor, DNA translocase Mfd, that enables bacteria to evolve rapidly by promoting mutations in many different bacterial species. This action speeds antibiotic resistance, including multi-drug resistance. […]
From the ashes of a failed pain drug, a new therapeutic path emerges November 16, 2018
A surprising discovery about a failed pain drug -- and specifically, the pathway it targets, BH4 -- could have implications for autoimmunity and cancer. Neuroscientists report that BH4 also functions as a kind of immunological thermostat, raising and lowering the activity levels of T cells. Inhibiting BH4 could relieve atopic dermatitis, psoriasis, lupus, polyarthritis and […]
Majority of HIV persistence during ART due to infected cell proliferation November 16, 2018
Study confirms biological mechanism responsible for latent HIV reservoirs; suggests strategies for a functional HIV cure.
Social isolation linked to higher risk of death November 16, 2018
A large study links social isolation with a higher risk of death from all causes combined and heart disease for all races studied, and with increased cancer mortality in white men and women.
New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire November 15, 2018
Researchers have devised a CRISPR-based system called SLICE, which will allow scientists to rapidly assess the function of each and every gene in 'primary' immune cells -- those drawn directly from patients. The new method, described in the Nov. 15 issue of Cell, provides researchers with a powerful tool that will guide their decision-making when […]
New inflammation inhibitor discovered November 15, 2018
A multidisciplinary team of researchers have developed an anti-inflammatory drug molecule with a new mechanism of action. By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation.
Enzymes in the cross-hairs November 15, 2018
More and more bacteria are resistant to available antibiotics. A team of chemists now presents a new approach: they have identified important enzymes in the metabolism of staphylococci. Blocking these enzymes in a targeted manner would allow the pathogens to be starved.
Cancer identity technology makes it easier to find a tumor's 'address' November 15, 2018
Researchers have developed a technology aimed at making it easier to deliver cancer treatment to the right 'address' in the body while also easing the painful side effects of chemotherapy on patients.

VentriPoint Diagnostics reports that its new approved heart technology being used by internationally renowned pediatric cardiologist November 20, 2018
Earlier this week, the firm said its VMS+ software had been approved for analyzing 3D echo images
Indivior shares plummet as it loses US court battle with India's Dr Reddy's November 20, 2018
Indivior said it was disappointed in the court ruling and would continue to "vigorously pursue" ongoing infringement cases against Dr Reddy's Laboratories
Genprex, Aldevron report progress in clinical trials for lung-cancer therapy Oncoprex November 20, 2018
Genprex will acquire more plasmid DNA vectors from Aldevron for its expanding clinical program at the MD Anderson Cancer Center
Takeda's proposed takeover of Shire receives conditional EU clearance November 20, 2018
The acquisition is expected to be completed on January 8, subject to shareholder approval
Nemaura Medical signs pact with Al-Danah Medical to launch painless sugarBEAT glucose monitor in Qatar November 20, 2018
It’s a strategic move to crack open the wealthy Qatar market, one of the largest potential markets for continuous glucose monitoring devices
Kroger chooses Cincinnati hometown for the first high-tech warehouses it plans to build with Ocado November 20, 2018
The US supermarket chain said it will spend US$55mln on the partners' first project - a 335,000-square-foot facility in Monroe, Ohio, a suburb north of Cincinnati
Boston Scientific eyes medical devices growth with £3.3bn BTG acquisition November 20, 2018
BTG said it plans to recommend the 840p per share deal to its shareholders as it considers the terms to be fair and reasonable
Genedrive Plc targeting its three assays on the market and revenue generating in 2-3 years November 20, 2018
David Budd, chief executive of genedrive Plc (LON:GDR), caught up with Proactive London's Andrew Scott after raising £5.6mln, net of expenses, through a successful placing of shares and the issue of convertible loan notes. Genedrive's also announced a proposal to raise up to a further £500,000 by way of a broker option to allow existing […]
Redx Pharma's CSO Richard Armer outlines development ambitions and clinical targets November 20, 2018
Redx Pharma Plc's (LON:REDX) chief scientific officer Richard Armer sat down with Proactive London's Andrew Scott to discuss the opportunities ahead for their cancer and fibrosis portfolios. Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year. Putative fibrosis treatment RXC006 is expected to enter the […]
SkinBioTherapeutics begins final phase of human study; commercial talks continue November 20, 2018
Provisional results for some of the volunteers will be available by the end of December with the full read-out expected in the first quarter of next year

STAT Plus: Only a few drug makers are actively targeting medicines needed in poor countries November 20, 2018
Amid growing pressure on the pharmaceutical industry to ensure people in low- and middle-income countries have access to needed medicines, a new report finds five large drug makers are doing…
STAT Plus: Pharmalittle: FDA to reduce use of dogs in tests; another setback for a Pfizer immunotherapy drug November 20, 2018
As part of a new effort to cut the use of dogs in drug trials, the FDA launched an initiative to keep canines out of studies for certain veterinary medicines.
STAT Plus: You have questions on biosimilars. We have answers November 20, 2018
What do patent thickets mean for biosimilars? How much cheaper are biosimilars than branded drugs? And what about "pay to delay" moves?
A drug maker boosted the price of its opioid-overdose antidote by 600 percent, and taxpayers suffered November 19, 2018
In order to capitalize on the opioid crisis, a small company that sells a version of naloxone, a decades-old drug that is widely used to reverse the effect of opioid…
STAT Plus: HHS watchdog chastises Mallinckrodt over a giveaway program for its pricey Acthar Gel drug November 19, 2018
The decades-old medication for infantile spasms has a controversial pricing history.
STAT Plus: Pharmalittle: AstraZeneca plans for its next CEO; FDA struggles with questions over drug costs November 19, 2018
AstraZeneca has begun succession planning for Pascal Soriot, its chief executive of six years, after pressure from shareholders.
STAT Plus: EpiPen may have a lot of value … but only if it costs $24 November 16, 2018
The auto-injectors deliver doses of epinephrine, using technology developed in the 1970s that was subsidized by the U.S. government.
STAT Plus: Up and down the ladder: The latest comings and goings November 16, 2018
Hired someone new and exciting? Promoting a rising star? Finally solved that hard-to-fill spot?
STAT Plus: Pharmalittle: AstraZeneca immunotherapy trial flops; Takeda shareholders trying to block Shire deal November 16, 2018
A dissident group of Takeda Pharmaceutical shareholders is making a final push to block its $62 billion acquisition of Shire.
STAT Plus: A big Indian generics maker failed an FDA inspection, but how bad was it? November 15, 2018
This facility has been in FDA crosshairs for some time.

BioInvent Signs Manufacturing Agreement With U.S. Cell Therapy Company
BioInvent International AB announced today that it has signed a manufacturing agreement with an undisclosed U.S. cell therapy company for the production of cGMP compliant material to support their clinical development programs.
Interview: Survey Numbers Show California’s Life Science Industry Is an Economic Powerhouse
The number of life science jobs grew by 12,500 for an approximate total of a total estimated employment of 311,226. That was music to the ears of Sara Radcliffe, president and chief executive officer of the California Life Sciences Association.
Tiziana Announces Pricing of Offering and Warrant Conversion Raising in Aggregate $5.79 million of New Equity Capital, Approval to List on the Nasdaq Global Market and Loan Conversion Extinguishing $1.78 million of Debt
Tiziana Life Sciences plc today announces the pricing of its underwritten initial public offering in the United States (the “Offering”) of 442,910 American Depositary Shares ("ADSs"), representing 4,429,100 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares") at an initial public offering price of $9.90 per ADS, before […]
Adding 120 N.C. Jobs, Seqirus to Spend $140 Million to Expand Flu Vaccine Plant
Seqirus, a wholly owned subsidiary of CSL, is expanding its manufacturing plant in North Carolina. It expects to invest $140 million in the expansion.
Industry Group BIO Publishes Global State-of-the-Industry Report
The Biotechnology Industry Organization (BIO) published the fifth edition of the Building the Bioeconomy report recently. The report studied 28 different indicators and provided analysis and insight into the biotech environment for 33 countries. The goal of the report is to determine how successf...
PellePharm’s Phase III Skin Disease Trial Is Back on Track Following Agreement With LEO Pharma
Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), two rare forms of skin cancer.
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis
Shanghai Roche Pharmaceuticals Ltd. and Ascletis BioScience Co., Ltd. jointly announce that starting from 1st Dec 2018, Ascletis and Roche will expand their partnership in viral Hepatitis.
Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference, November 28, 2018
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
Ipsen and 3BP today announced the first patient has been dosed in a Phase I/II study for the first-in-class radionuclide 177Lu-IPN01087 (formerly known as 3BP-227).
Curis to Present at the 60th Annual Meeting of the American Society of Hematology
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology.